Press "Enter" to skip to content

Bristol-Myers wins $752 million in U.S. patent case against Gilead

A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead’s Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers’ Juno Therapeutics division.

Original source: https://health.economictimes.indiatimes.com/news/pharma/bristol-myers-wins-752-million-in-u-s-patent-case-against-gilead/72576595?utm_source=RSS&utm_medium=ETRSS

Also Read:   Scientists identify hundreds of drug candidates to treat Covid-19